HYPR Stock Jumps on NVIDIA Partnership to Advance AI Neuroimaging

Hyperfine, Inc. HYPR recently announced a strategic collaboration with NVIDIA to integrate advanced AI technologies into its Swoop Portable magnetic resonance imaging (MRI) system. This partnership aims to accelerate the development of AI-powered neuroimaging solutions, enhancing the speed and accessibility of brain scans.The collaboration underscores Hyperfine’s commitment to revolutionizing neuroimaging by combining its portable MRI technology with NVIDIA’s cutting-edge computational platforms. This move positions Hyperfine to improve patient outcomes further and expand its leadership in point-of-care imaging.Likely Trend of HYPR Stock Following the NewsFollowing the announcement, shares of the company surged 39.3% and closed at $1.28 on Monday. In the past six months, HYPR shares have gained 33.3% against the industry’s 9.2% decline. The S&P 500 improved 1.3% in the same time frame.This collaboration can further boost HYPR's stock price in the long term, as integrating NVIDIA’s AI technology should make Hyperfine’s MRI systems faster, smarter, and more accessible. It strengthens its competitive edge in the growing portable imaging market, potentially attracting more hospitals and healthcare providers. As demand increases, revenue growth and market share could improve, making the stock more appealing to investors. Additionally, partnerships with industry leaders like NVIDIA often build investor confidence in the company’s innovation pipeline and future potential.Meanwhile, HYPR currently has a market capitalization of $93.4 million. The company delivered an earnings surprise of 12.5% in the last reported quarter.Image Source: Zacks Investment ResearchDetails on Hyperfine & NVIDIA PartnershipOver three billion people suffer from brain diseases globally, yet the majority of them lack timely MRI access due to the high costs and infrastructure needs of traditional MRI systems. Hyperfine’s AI-powered portable MRI addresses this by providing affordable, point-of-care imaging that any trained clinician can operate, thereby bridging critical gaps in global healthcare access.Hyperfine’s Swoop Portable MRI system is the world’s first FDA-cleared, portable MRI designed for bedside use. Unlike traditional MRI machines, the Swoop system is compact and mobile, allowing medical staff to conduct brain scans directly at a patient’s bedside. It helps deliver rapid neuroimaging results without the need to transport critically ill patients, improving safety, speed, and accessibility, especially in emergency and intensive care settings.The collaboration between Hyperfine and NVIDIA is likely to focus on advancing AI-powered image reconstruction and embedding real-time clinical decision support into portable MRI workflow. By leveraging NVIDIA’s advanced suite of training and inference tools, such as NVIDIA DALI and MONAI, the collaboration aims to enhance the Swoop system’s image quality further, reduce scan times, and enable faster and more reliable diagnoses.HYPR’s Recent DevelopmentsRecently, HYPR reported its fourth-quarter and full-year 2024 results. In 2024, Hyperfine reported $12.89 million in revenues (up 17%) and sold 48 Swoop MRI systems, improving its gross margin to 46%. The net loss narrowed to $40.72 million, driven by reduced expenses and $37.64 million in cash reserves. For 2025, management expects revenue growth of 20%-30% and targets a 32% reduction in cash burn to $25-$27 million, with the projected first-half 2025 revenues of around $6 million.HYPR’s Zacks Rank & Stocks to ConsiderHYPR carries a Zacks Rank #3 (Hold) at present.Some better-ranked stocks in the broader medical space are Masimo MASI, Boston Scientific BSX and Cardinal Health CAH. At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Masimo’s shares have rallied 30.1% in the past year. Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have gained 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Hyperfine, Inc. (HYPR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks